

Follow us on Twitter:

@EU Health @Food EU

From: Sent		@curevac.com>	
To	(NTF)	@ec.europa.eu>	
		@pm.gouv.fr>; @urpl.gov.pl;	
	(COMP)	@ec.europa.eu>;	1
	@ec.europa	@igf.finances.gouv.fr;	
(SANTF)	@ec.e	europa.eu>	
Cc.		@yahoo.com>;	
	@curevac.com>;	@curevac.com>	
Subject: RE:			
Dear			
Dear			
1.700			
Dear			

Thank you for the recent discussions and exchanges. Please find attached CureVac's that reflects the agreement we have reached today on key Please let me know if some elements are not clear or completely aligned with your notes.

We understand that the discussion will now shift to other key contractual topics such as and that you would share with us the current EC position

on the topic to kick off the discussion. In parallel, we also understand that you will be able to begin Member States

In addition we will share in the coming days a confidential update on which you can share with the scientific/technical assessment teams of member states, under confidentiality. We remain interested in the live scientific exchange platform that I understand would be organized with member states towards end august to present further data, explain the distinctiveness of our mRNA platform, and generally adress any questions the expert teams from Member States may have.

We look forward to rapidly moving towards a full and firm agreement.

Best regards